首页> 外文期刊>ChemMedChem >Structure–Activity and Structure–Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity
【24h】

Structure–Activity and Structure–Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity

机译:双阶段抗蛋白活性的拟拟拟拟肽组蛋白脱乙酰酶抑制剂的结构 - 活性和结构毒性关系

获取原文
获取原文并翻译 | 示例
           

摘要

Novel malaria intervention strategies are of great importance, given the development of drug resistance in malaria-endemic countries. In this regard, histone deacetylases (HDACs) have emerged as new and promising malaria drug targets. In this work, we present the design, synthesis, and biological evaluation of 20 novel HDAC inhibitors with antiplasmodial activity. Based on a previously discovered peptoid-based hit compound, we modified all regions of the peptoid scaffold by using a one-pot multicomponent pathway and submonomer routes to gain a deeper understanding of the structure–activity and structure–toxicity relationships. Most compounds displayed potent activity against asexual blood-stage P. falciparum parasites, with IC50 values in the range of 0.0052–0.25 mm and promising selectivity over mammalian cells (SI~(Pf3D7/HepG2): 170– 1483). In addition, several compounds showed encouraging sub-micromolar activity against P. berghei exo-erythrocytic forms (PbEEF). Our study led to the discovery of the hit compound N-(2-(benzylamino)-2-oxoethyl)-N-(4-(hydroxycarbamoyl) benzyl)-4-isopropylbenzamide (2h) as a potent and parasite- specific dual-stage antiplasmodial HDAC inhibitor (IC_(50) Pf3D7=0.0052 μm, IC50PbEEF=0.016 μm).
机译:鉴于疟疾流行国家的耐药性的发展,新型疟疾干预策略具有重要意义。在这方面,组蛋白脱乙酰酶(HDACs)被出现为新的和有前途的疟疾药物靶标。在这项工作中,我们提出了20种新型HDAC抑制剂的设计,合成和生物学评价,具有抗癌症活性。基于先前发现的基于拟拟拟肽的麦白化合物,我们通过使用单盆多组分途径和亚眠单元途径改进了肽支架的所有区域,以获得对结构 - 活性和结构毒性关系的更深层次的理解。大多数化合物对无形性血液阶段P. falciparum寄生虫呈现有效的活性,IC50值在0.0052-0.25 mm的范围内,并且对哺乳动物细胞的有希望的选择性(Si〜(PF3D7 / Hepg2):170-1483)。此外,几种化合物显示出对P. Berghei Exo-Erythrocytic形式(PBEEF)的次微摩尔活性。我们的研究导致发现麦片化合物N-(2-(苄基氨基)-2-氧乙基)-N-(4-(羟基氨基甲酰基)苄基)-4-异丙基苯甲酸苄酰胺(2H),为有效和寄生虫特异性的双重 - 阶段抗溶质HDAC抑制剂(IC_(50)PF3D7 =0.0052μm,IC50PBEEF =0.016μm)。

著录项

  • 来源
    《ChemMedChem》 |2019年第9期|共15页
  • 作者单位

    Pharmaceutical/Medicinal Chemistry Institute of Pharmacy Medical Faculty Leipzig University Brederstrasse 34 04103 Leipzig (Germany);

    Griffith Institute for Drug Discovery Griffith University Don Young Road Nathan QLD 4111 (Australia);

    Department of Pediatrics School of Medicine University of California San Diego 9500 Gilman Drive 0741 La Jolla CA 92093 (USA);

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号